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ABSTRACT
Objective: This study was aimed to develop a highly sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method 
for the simultaneous quantification of tamoxifen, endoxifen, and clomiphene (internal standard) levels in human plasma.
Methods: Plasma samples from 40 patients with breast cancer were prepared through liquid–liquid extraction in ethyl acetate, and chromatographic 
separation was performed on an Acquity UPLC BEH C18 column (1.7 µm, 2.1 mm×100 mm). The sample was eluted within 6.50 min at a flow rate of 
0.200 ml/min under a gradient of 0.2% formic acid and acetonitrile. The analytes were then quantified through triple quadrupole MS with electrospray 
ionization in the positive ion mode and multiple reaction monitoring.
Results: The method was successfully used to quantify the plasma levels of tamoxifen and endoxifen, yielding respective measurement ranges 
of 42.19–249.23 ng/ml and 1.52–26.62 ng/ml. Overall, this detection method was sensitive, with lower limits of quantitation of 0.625 ng/ml for 
tamoxifen and 0.125 ng/ml for endoxifen. In addition, this method was precise and accurate, with a between-run variation range of 5.19–12.38% and 
%diff range of −10.82%–+13.10%.
Conclusion: This method demonstrated that approximately 80% of patients had plasma levels of endoxifen exceeding the expected clinical threshold 
(5.9 ng/ml). This rapid and simple method could be used to monitor tamoxifen metabolism and adjust doses as needed to achieve maximum 
effectiveness.
Keywords: 4-Hydroxy-N-desmethyltamoxifen (endoxifen), Breast cancer, Clomiphene, Liquid chromatography-tandem mass spectrometry, 
Tamoxifen, Validation.
INTRODUCTION
The first-generation selective estrogen receptor (ER) modulator 
tamoxifen was initially approved by the US food and drug administration 
in 1977, which has been used as an endocrine therapy for more than 
three decades in women with ER+ breast cancer or a high risk of 
this disease [1-4]. Tamoxifen (TAM) competitively inhibits estrogen 
binding to the ER, thus inhibiting the estrogen-dependent growth and 
proliferation of epithelial breast cancer cells [3].
TAM itself is a prodrug and is biotransformed into several metabolites 
including 4-hydroxy-N-desmethyltamoxifen (endoxifen), which has 
been shown to exhibit an antiestrogenic activity level of 30–100-
fold more potent than that of tamoxifen. The considerably elevated 
concentration of endoxifen relative to 4-hydroxy-tamoxifen (5–10-fold) 
contributes to its effects as a potent metabolite responsible for the 
pharmacological effects of tamoxifen [2,3,5-11].
As endoxifen formation and concentration are essential mediators of 
the clinical outcomes of tamoxifen, variations in patients’ responses 
in terms of efficacy and toxicity have led to failures or resistance to 
tamoxifen therapy [11-14]. The cytochrome P450 family member 
CYP2D6, an enzyme that plays a critical role in tamoxifen metabolism, 
is encoded by a highly polymorphic gene with >100 known alleles. 
This genetic polymorphism has been suggested as a potential 
cause of the considerable interindividual variation in endoxifen 
concentrations among patients [3-5,7,12,15,16]. Therefore, both 
endoxifen concentration monitoring and dose adjustments are 
important to the achievement of effective therapeutic responses among 
patients using tamoxifen [8,11,12].
Previously, Madlensky et al. reported a correlation between the clinical 
outcomes of tamoxifen and the serum concentration of endoxifen and 
suggested that an adequate therapeutic effect is dependent on the 
achievement of a plasma threshold concentration. Specifically, patients 
with plasma endoxifen levels exceeding 5.9 ng/ml at steady state had a 26% 
reduction in the risk of recurrence, compared with patients having plasma 
endoxifen levels below this threshold [17,18]. Although several methods 
have been developed to monitor and quantify the concentrations of 
tamoxifen and its metabolites in human biological fluids [5-7,11,13,14,17], 
a rapid, simple, and highly-sensitive method is required for the regular 
monitoring of plasma levels from breast cancer patients. Herein, we 
describe the development and validation of a more selective and sensitive 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) method 
for the simultaneous quantification of tamoxifen and endoxifen in human 
plasma within a comparatively short duration of analysis. We further 
report the application of this method to clinical samples from breast cancer 
patients in an attempt to monitor endoxifen plasma concentrations.
METHODS
Reagents
TAM citrate was obtained from Chemo (Lugano, Switzerland). 
4-Hydroxy-N-desmethyl-tamoxifen in a 1:1 E/Z mixture (endoxifen) 
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was purchased from Tocris Bioscience (Bristol, UK). Clomiphene 
citrate was obtained from Fabbrica Italiana Sintetici (Milano, Italy) 
and used as the internal standard (IS). All chemicals were of analytical 
grade or higher. High-performance liquid chromatography-grade 
acetonitrile and methanol, formic acid, ethyl acetate, n-hexane, and 
dichloromethane were purchased from Merck (Darmstadt, Germany). 
Blank citrated human plasma was purchased from the Indonesian Red 
Cross Society (Jakarta, Indonesia).
Equipment
A Water Acquity series Ultra Performance LC-MS/MS system was used 
for the chromatographic separation and quantitative measurement 
of analytes. This system comprised a high-pressure binary pump, 
autosampler, Acquity UPLC® BEH C18 column (Waters, Milford, 
MA, USA) equipped with Van Guard™ BEH precolumn, and a triple 
quadrupole mass spectrometer (Xevo TQD, Waters).
Standards
Stock solutions of 1000 µg/ml tamoxifen, endoxifen, and clomiphene 
citrate were prepared individually by dilution with methanol and 
were subsequently stored at −20°C. These solutions were then diluted 
appropriately with methanol - water (1:1) to obtain working solutions 
ranging from 0.0625 to 25 µg/ml for tamoxifen and 0.0125 to 10 µg/ml 
for endoxifen; the working concentration of the IS was 1000 ng/ml. 
For each run, calibration standards were freshly prepared by spiking 
10 µl aliquots of working solution into 990 µl aliquots of blank citrated 
plasma to obtain concentrations ranging from 0.625 to 250 ng/ml for 
tamoxifen and 0.125 to 100 ng/ml for endoxifen. Three corresponding 
quality control (QC) samples - low, medium, and high - were also 
prepared by spiking 10 µl aliquots of working solution into 990 µl 
aliquots of blank citrated plasma to obtain concentrations ranging from 
0.5 to 200 ng/ml. QC samples were stored at −20°C before the analysis.
Sample preparation and extraction
A 200 µl aliquot of plasma was mixed with 50 µl of IS solution (1 μg/ml 
clomiphene in methanol - water [1:1, v/v]), vortexed for 10 s, and added 
to 1000 µl of ethyl acetate. This mixture was again vortexed for 2 min 
and centrifuged for 10 min at 10,000 rpm and ambient temperature. 
A 750 µl aliquot of the organic phase was then transferred into a glass 
tube and evaporated to dryness under nitrogen at 60°C. Subsequently, 
the residue was reconstituted in 100 µl of a mixture of acetonitrile 
and formic acid (30:70, v/v), vortexed and sonicated for 10 s, and 
centrifuged for 5 min at 3000 rpm. Finally, a 5 µl aliquot of supernatant 
was injected into the LC-MS/MS system.
LC-MS/MS conditions
Chromatographic conditions
Chromatographic separation was performed on an Acquity UPLC® 
BEH C18 column (1.7 µm; 100 mm×2.1 mm) at a column temperature 
of 30°C. Formic acid (0.2%, v/v) and acetonitrile were used as mobile 
phases A and B, respectively. To separate the analytes, a gradient elution 
was performed at a flow rate of 0.200 ml/min. A linear increase in phase 
B from 30% to 65% was initiated over 1 min, followed by an increase 
to 95% over 2 min. Phase B was then decreased to the initial condition 
over 1 min, and the system was then held for 1.5 min to re-equilibrate 
before the subsequent injection. The total run time for each analysis 
was 6.50 min, and the injection volume was 5 µl.
Mass spectrometry detection
MS/MS detection was performed through electrospray ionization (ESI) 
in a positive ion mode and multiple-reaction monitoring. The MS/MS 
parameters were optimized automatically and determined by directly 
infusing the analytes and IS solutions independently into the MS/MS 
detector at a concentration of 10 μg/ml in methanol:water (1:1). The 
desolvation gas settings were a temperature of 450°C and flow of 
800 l/h, with a capillary voltage of 3.5 kV. The selected m/z transitions, 
cone voltage, and collision energy of each analyte and the IS are 
summarized in Table 1.
Method validation
The LC-MS/MS method was validated in accordance with the Guideline 
on Bioanalytical Method Validation, as published by the European 
Medicines Agency (EMA) [19]. Calibration curves were generated using 
the IS method and by correlating the peak area ratio of each analyte 
to the IS with the actual concentration spiked into blank plasma. The 
seven points in the calibration curve (excluding the blank and chosen 
zero) were 0.125, 1, 2, 5, 10, 50, and 100 ng/ml for endoxifen and 
0.625, 5, 10, 25, 50, 200, and 250 ng/ml for tamoxifen. Back-calculated 
concentrations were obtained, and linearity was assessed using the 
coefficient of correlation (r). The lower limit of quantification (LLOQ) 
for each analyte was expressed as the lowest concentration that could 
be measured quantitatively; these values were 0.125 and 0.625 ng/ml 
for endoxifen and tamoxifen, respectively.
Three corresponding concentrations of QC samples within the 
calibration ranges were also used within the validation to represent the 
estimated drug levels in patient samples. The precision and accuracy of 
the method were determined in three runs performed on two different 
days. Precision was described as the coefficient of variation (CV %), 
whereas accuracy was defined as the bias or the difference between 
the actual and measured nominal (diff %). Selectivity was assessed 
by observing the presence of interfering compounds in blank samples 
from six different sources. Carryover was also calculated based on the 
peak area response in blank plasma after the injection of a high QC 
sample, compared with the peak area response of the analyte at the 
LLOQ. The matrix effect (ME) was assessed using the post-extraction 
spiked method to determine whether the plasma matrix suppressed 
or enhanced ionization during MS/MS. The matrix factor (MF) was 
calculated by comparing the peak area response of the analyte spiked 
after extraction with the peak area response of the analyte in solution. 
At least six different plasma sources were used. An IS-normalized MF 
was also calculated by dividing the MF of the analyte with the MF of 
the IS. Extraction recovery represented the efficiency of the extraction 
method and was calculated by comparing the peak area responses of 
the extracted analytes and the IS in plasma samples with the peak area 
responses of the analytes and IS in solution (unextracted). Meanwhile, 
dilution integrity was analyzed to ensure that the dilution of samples 
would not affect the precision and accuracy of the quantification 
method.
The stability of the stock solutions and the analytes in plasma samples 
were tested under the following conditions:
a) Stability of the analytes and IS stock solutions at ambient temperature 
for up to 24 h and at −20°C for up to 45 days.
b) Stability of the analytes in plasma samples at ambient temperature 
and at −20°C for up to 45 days.
c) Stability of the analytes in plasma samples after three consecutive 
freeze-thaw cycles. The samples were kept frozen for 24 h and 
allowed to thaw at ambient temperature for approximately 1 h.
d) Stability of extracted samples in an autosampler at ambient 
temperature for up to 24 h.
Application of the method to clinical samples
Blood samples were obtained from consenting breast cancer patients 
enrolled in a study approved by the Research Ethics Committee of 
Universitas Indonesia and Cipto Mangunkusumo Hospital (HREC-
FMUI/CMH). A total of 40 patients who had received adjuvant 
tamoxifen (20 mg/day) hormonal therapy for at least 2 months were 
enrolled in the study after providing written informed consent. All 
patients fulfilled the following inclusion criteria: Diagnosis with ER+ 
breast cancer, therapeutic regimen including 20 mg/day, and an age of 
30–60 years at the time of blood collection. Patients were excluded if 
they met the following criteria: Had not received tamoxifen therapy for 
>2 months and a declaration of unwillingness to participate in the study 
(i.e., refusal to provide signed informed consent).
Venous blood (3 ml) was collected into EDTA-containing tubes by 
venipuncture at random time points after the last drug intake. The 
 The 2nd Physics and Technologies in Medicine and Dentistry Symposium (PTMDS), Universitas Indonesia. Depok, Indonesia 372
Int J App Pharm, Vol 10, Special Issue 1, 2018
 Harahap et al. 
blood was immediately centrifuged, and plasma was transferred to a 
polypropylene tube, stored at −80°C until analysis, and analyzed within 
1.5 months. Before the analysis, the samples were thawed; 200 µl of 
plasma was collected, and 50 µl of IS was added before extraction.
RESULTS AND DISCUSSION
LC-MS/MS conditions and methodologic development
The developed LC-MS/MS method enables the simultaneous 
quantification of tamoxifen and endoxifen in plasma within a short 
run time (6.50 min). TAM and endoxifen were successfully separated 
and eluted within 4.5 min, with elution times of 4.01 and 3.45 min for 
tamoxifen and endoxifen, respectively. Subsequently, a linear gradient 
was followed by 1.5 min of column re-equilibration.
The selected daughter ions of tamoxifen, endoxifen, and IS are 
presented in Table 1 and were selected based on their highest relative 
abundances. The daughter ions at m/z 72.22, 58.20, and 100.17 were 
identified as the dominant visible signals in the mass spectra for 
tamoxifen, endoxifen, and IS, respectively. An ESI-positive setting was 
used because of the basic nature of the analytes, and liquid–liquid 
extraction with ethyl acetate was applied to yield better recovery and 
cleaner extracts compared with protein precipitation.
Method validation
The measurement of drug concentrations in biological samples, an 
important aspect, requires a well-characterized method to obtain 
reliable results [20]. In this study, the method was validated using 
criteria defined by the EMA guidelines, such as selectivity, sensitivity, 
accuracy and precision, carry-over, ME, dilution integrity, and stability. 
The selectivity test revealed no interfering peaks in blank plasma 
samples from six sources, indicating a lack of selectivity issues. The 
calibration curves were linear, with r value >0.994, and concentrations 
of endoxifen and tamoxifen ranging from 0.125 to 100 ng/ml and from 
0.625 to 250 ng/ml, respectively, could be measured. The method 
was also twice as sensitive as previously reported methods and thus 
enabled the quantification of both endoxifen and tamoxifen even at 
lower plasma concentrations, with LLOQ values of 0.125 ng/ml for 
endoxifen and 0.625 ng/ml for tamoxifen [5,11,14].
The precision and accuracy of the method were assessed both within-
run and between-run and were determined using the CV% and diff %. 
The measured precision and accuracy are shown in Table 2. All three 
tested concentrations of QC samples and samples at the LLOQ were 
within the accepted criteria as specified by the EMA, namely a CV% 
and diff % within ±15% and within ±20% for the LLOQ. Carryover 
and dilution integrity were also tested, and both fulfilled the criteria 
of acceptance.
MEs for every quantification method were evaluated using MS and 
determined using a post-extraction spiked method, in agreement 
with previous studies [5,11]. The results are reported in Table 3. The 
analytical results of the extracted blank plasma spiked with analytes 
(a) were compared with those of the analytes in solution (b). The mean 
peak ratio of A/B (Table 3) indicated a slight effect on the analyte 
signals, which might be due to ion suppression. However, a similar 
ion suppression was observed in IS; therefore, the ratio of A/B when 
normalized to the IS indicates the use of the IS for compensating the 
MEs. Overall, the values of the IS-normalized MF remained within the 
acceptable range of 0.80–1.20 and indicated non-significant MEs in the 
MS/MS responses of analytes when using IS [20]. Extraction recoveries 
(ER) were also determined using a similar method and were evaluated 
by comparing the peak area of the extracted analytes in plasma samples 
(c) with the peak area response of the analytes in solution unextracted 
(d) The recovery values of the analytes and IS (Table 4) were shown to 
meet the criterion of acceptable precision.
The stability of the analyte stock solutions was tested using the 
results of stable analytes with variations <10% when held at ambient 
temperature for up to 24 h and at −20°C for up to 45 days. Analytes 
in plasma samples (observed using QC samples) were deemed stable 
if they were maintained at ambient temperature up to 24 h and in 
storage conditions of −20°C for up to 45 days. Longer-term stability 
(i.e. longer storage period) was not investigated further. The analytes 
were also found to be stable after three consecutive freeze-thaw cycles 
of samples, consistent with previous reports [5,11,14]. Moreover, 
an autosampler stability test also indicated the stability of analytes 
left in the autosampler at ambient temperature for up to 24 h. The 
variations observed during these stability tests were <15%, indicating 
no noticeable impacts on analyte concentrations.
Clinical application
The developed method was applied to the quantification of tamoxifen 
and endoxifen concentrations in plasma samples from 40 patients 
treated with regimens containing tamoxifen at 20 mg/day. The 
Table 1:MS/MS parameters
Analyte Parent (m/z) Daughter (m/z) Cone voltage (V) Collision (V)
TAM 372.22 72.22 40 30
END 374.29 58.20 45 30
Clomiphene 406.28 100.17 40 25
MS: Mass spectrometry, TAM: Tamoxifen, END: Endoxifen
Table 2: Within-run and between-run variations of the LLOQ and QC samples
Sample Actual value (ng/mL) Within-run Between-run
Measured 
value (mean±SD; ng/mL)
CV (%) Bias (%) Measured value  
(mean±SD; ng/mL)
CV (%) Bias (%)
TAM
LLOQ 0.625 0.64±0.07 10.6 2.85 0.62±0.08 12.38 −0.67
Low 2.5 2.61±0.19 7.33 4.21 2.65±0.18 6.97 6.2
Medium 125 125.77±6.74 5.36 0.62 128.05±6.8 5.31 2.44
High 200 190.21±6.02 3.17 −4.89 192.52±9.99 5.19 −3.74
END
LLOQ 0.125 0.13±0.01 11.11 6.08 0.13±0.01 10.3 5.04
Low 0.5 0.53±0.04 7.57 6.11 0.53±0.03 6.05 6.68
Medium 50 51.87±3.37 6.5 3.74 53.08±2.93 5.53 6.17
High 75 76.26±3.64 4.78 1.68 74.88±3.94 5.26 −0.16
LLOQ: Lower limit of quantification, SD: Standard deviation, CV: Coefficient of variation, TAM: Tamoxifen, END: Endoxifen
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patients’ ages ranged from 34 to 60 years (mean age=44.9 years). The 
median time interval between the initiation of tamoxifen therapy and 
the collection of a blood sample for analysis was 13.5 months (range: 
2–84 months). The characteristics of the 40 patients enrolled in this 
study are listed in Table 5.
The plasma concentrations of tamoxifen and endoxifen were measured 
using the LC-MS/MS method, and the median and mean plasma 
concentrations are shown in Table 5. The steady-state concentrations 
of analytes varied widely among patients, with a difference of 16.93% 
between the lowest (42.19 ng/ml) and highest (249.23 ng/ml) tamoxifen 
concentrations and 17.63% between the lowest (1.51 ng/ml) and 
highest (26.62 ng/ml) endoxifen concentrations. The median plasma 
concentrations of tamoxifen and endoxifen were 232.48 and 9.23 ng/ml, 
respectively. This difference was consistent with the results of a previous 
study [12]. The CVs (%) of the measured tamoxifen and endoxifen 
values were 27.45% and 57.83%, respectively. The average tamoxifen 
and endoxifen levels were 202.37 and 10.41 ng/ml, respectively. The 
analysis detected tamoxifen and endoxifen in all samples. The results 
showed in Fig. 1, Table 6, and Table 7.
In these patients, tamoxifen had already been metabolized to endoxifen; 
therefore, high levels were expected to yield an anticancer effect. The 
clinical efficacy of tamoxifen therapy was suggested to depend on 
the endoxifen plasma level threshold, which was 5.90 ng/ml [18-22]. 
Overall, nine patients (22.5% of total samples) had endoxifen plasma 
concentrations below this predefined threshold value, indicating that 
these patients were experiencing a lower level of therapeutic efficacy.
All patients received the same tamoxifen dose but harbored different 
plasma endoxifen concentrations, indicating that the formation of 
this metabolite did not depend on the initial prodrug dose alone. Low 
plasma levels of endoxifen might be attributed to a high consumption of 
inhibitory drugs and/or polymorphisms in CYP2D6 or other enzymes 
requiring further evaluation. Notably, CYP2D6, the main enzyme 
Table 3: ME of plasma samples
Concentration (ng/mL) 2.5 200
MF (%) IS-normalized MF MF (%) IS-normalized MF
Mean±SD CV (%) Mean±SD CV (%) Mean±SD CV (%) Mean±SD CV (%)
TAM 85.36±5.61 6.58 0.88±0.05 5.96 88.50±5.41 6.11 0.91±0.05 5.44
Concentration (ng/mL) 0.5 75
END 78.10±5.61 7.19 0.81±0.04 5.12 91.03±3.26 3.58 0.94±0.05 5.36
Concentration (ng/mL) 1000
Clomiphene (IS) 97.02±7.91 8.15
ME: Matrix effect, SD: Standard deviation, IS: Internal standard, CV: Coefficient of variation, MF: Matrix factor, TAM: Tamoxifen, END: Endoxifen
Table 4: Extraction recovery of plasma samples
Concentration (ng/mL) 2.5 125 200
Extraction recovery (%)
Mean±SD CV (%) Mean±SD CV (%) Mean±SD CV (%)
TAM 77±6.93 9 83.35±4.34 5.21 72.05±2.94 4.29
Concentration (ng/mL) 0.5 50 75
END 69.21±7.64 11.04 83.86±5.68 6.77 81.89±2.65 3.24
Concentration (ng/mL) 1000
Clomiphene (IS) 86.72±2.98 3.44
ME: Matrix effect, SD: Standard deviation, IS: Internal standard, CV: Coefficient of variation, MF: Matrix factor, TAM: Tamoxifen, END: Endoxifen








Sampling time (hours after last drug intake)
Range 1–23.5
TAM: Tamoxifen
Fig. 1: Bar chart of the results of tamoxifen and endoxifen analyses in samples from 40 patients.  TAM: Tamoxifen; END: Endoxifen
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involved in tamoxifen metabolism, converts tamoxifen into the potent 
and highly abundant metabolite, endoxifen. Therefore, homozygosity 
for functional CYP2D6 alleles is required to achieve a high plasma 
level of endoxifen. Approximately 30% of people of Asian ethnicity are 
known to be intermediate metabolizers of tamoxifen, in whom only half 
of the alleles are fully functional [6]. Another potential critical factor 
affecting the overall steady-state endoxifen level may be the degree of 
compliance with tamoxifen therapy. Notably, some patients in this study 
were found to have not routinely taken their daily doses of tamoxifen 
during the sample collection period. Variability in exposure to 
endoxifen may lead to variability in the treatment outcomes. Therefore, 
tamoxifen dose adjustments based on the therapeutic drug monitoring 
of endoxifen concentrations may be warranted.
CONCLUSION
In this study, we developed and validated a highly sensitive and selective 
method for the simultaneous quantification of tamoxifen and endoxifen 
in human plasma during a relatively short gradient elution period of 
6.50 min. This method enables a good chromatographic separation of 
analytes, with LLOQ values of 0.625 and 0.125 ng/ml for tamoxifen and 
endoxifen, respectively. This method has finally allowed us to achieve the 
quantification of endoxifen in plasma samples from breast cancer patients, 
which is important to the achievement of effective tamoxifen therapy.
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